

Charles Lister
28/09/2000 13:30

Sent by: Charles Lister/HSD2

To: Mike McGovern/HSD2/DOH/GB@GRO
cc: lorna.williamson@GRO-C
Jill Taylor/HSD7/DOH/GB@GRO

Subject: OCTAPHARMA & FFP

Mike

As you'll see from other E-mails we are pursuing the question of what action (if any) should be taken in response to Octapharma's press release on FFP/Octaplas. Meanwhile there are two things you should know:

- Angela Robinson knows Jonathan Freeman, the consultant anaesthetist, given as a contact in Octapharma's press release. She has spoken to him and assures me that he has had no association with Octapharma for the past two years and was totally unaware that his name had been used in this way. I have therefore not pursued this further.
- Brian Stack spoke to me today - having first contacted Alan Harvey about the SEAC meeting. He told me that he merely wanted to remind the Department that Octapharma are ready to supply the NHS need for FFP either from German or US-sourced plasma. He told me that he has also spoken to Lorna Williamson and is aware of the risk assessment work being undertaken. I said that, as part of the risk assessment, we would be looking at a number of options around FFP and that the greater use of other products such as Octaplas would no be one of them.

Charles